Aravind Sanjeevaiah

Dr. Aravind Sanjeevaiah


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2009 in Circulation Research
Verified
Journal Article
Closed access
DTDmitry O. Traktuev
Dmitry O. Traktuev
DPDaniel N. Prater
Daniel N. Prater
SMStephanie Merfeld-Clauss
Stephanie Merfeld-Clauss
ASAravind Sanjeevaiah
Aravind Sanjeevaiah
MSM. Reza Saadatzadeh
M. Reza Saadatzadeh
KMKeith L. March
Keith L. March
Rapid induction and maintenance of blood flow through new vascular networks is essential for successfully treating ischemic tissues and maintaining function of engineered neo-organs. We have previously shown that human endothelial progenitor cells (EPCs) form functioning vessels in mice, but these are limited in number and persistence; and also that human adipose stromal cells (ASCs) are multipotent cells with pericytic properties which can stabilize vascular assembly in vitro. In this study, we tested whether ASCs would cooperate with EPCs to coassemble vessels in in vivo implants. Collagen implants containing EPCs, ASCs, or a 4:1 mixture of both were placed subcutaneously into NOD/SCID mice. After a range of time periods, constructs were explanted and evaluated with regard to vascular network assembly and cell fate; and heterotypic cell interactions were explored by targeted molecular perturbations. The density and complexity of vascular networks formed by the synergistic dual-cell system was many-fold higher than found in implants containing either ASCs or EPCs alone. Coimplantation of ASCs and EPCs with either pancreatic islets or adipocytes produced neoorgans populated by these parenchymal cells, as well as by chimeric human vessels conducting flow. This study is the first to demonstrate prompt and consistent assembly of a vascular network by human ASCs and endothelial cells and vascularization by these cells of parenchymal cells in implants. Mixture of these 2 readily available, nontransformed human cell types provides a practical approach to tissue engineering, therapeutic revascularization, and in vivo studies of human vasculogenesis.

1 January 2020 in Radiology
Verified
Journal Article
Closed access
JUJacob J. Underwood
Jacob J. Underwood
RQRehan S. Quadri
Rehan S. Quadri
SKSanjeeva P. Kalva
Sanjeeva P. Kalva
HSHriday Shah
Hriday Shah
ASAravind Sanjeevaiah
Aravind Sanjeevaiah
PSPatrick D. Sutphin
Patrick D. Sutphin
Understanding the utility of liquid biopsy is necessary to prepare for the challenges that will arise in the current diagnostic workflow of many cancers and to anticipate the additional opportuniti... Imaging and image-guided procedures play an imperative role in the screening, diagnosis, and surveillance of cancer. Although emerging imaging techniques now enable more precise molecular character...

27 August 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
RGRajashekhar Gangaraju
Rajashekhar Gangaraju
MKMalgorzata Kamocka
Malgorzata Kamocka
AMAbby Marin
Abby Marin
MSMark A. Suckow
Mark A. Suckow
WWWilliam R. Wolter
William R. Wolter
Matthias ClaussMatthias Clauss
Matthias Clauss

1 October 2007 in Endocrine Practice
Verified
Journal Article
Closed access
ASAravind Sanjeevaiah
Aravind Sanjeevaiah
SSSubbarayappa Sanjay
Subbarayappa Sanjay
TDTejesweni Deepak
Tejesweni Deepak
ASArdanareshwaran Sharada
Ardanareshwaran Sharada
SSSri S. Srikanta
Sri S. Srikanta

3 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Suleyman GoksuSuleyman Goksu
Suleyman Goksu
Muhammet OzerMuhammet Ozer
Muhammet Ozer
SKSyed Kazmi
Syed Kazmi
NSNina N Sanford
Nina N Sanford
TATodd A. Aguilera
Todd A. Aguilera
MBMuhammad Shaalan Beg
Muhammad Shaalan Beg
Background: We aimed to study the effect of socioeconomic differences and molecular characteristics on survival in patients with young-onset pancreatic neuroendocrine tumors (YOPNET) and typical-onset PNET (TOPNET). Methods: We identified the patients with YOPNET (<50 years) and TOPNET (≥50 years) who underwent definitive surgery diagnosed between 2004 and 2016 using the National Cancer Database. We evaluated overall survival (OS) using the Kaplan–Meier and Cox regression methods before and after propensity score matching. A publicly available genomic dataset was used to compare mutation frequencies among the two groups. Results: A total of 6259 patients with PNET were included, of which 27% were YOPNET. Patients with YOPNET were more likely to be Black, Hispanic, female, and have private insurance versus patients with TOPNET (all p < 0.001). Patients with YOPNET had a lower comorbidity score, but higher stage and tumor size (all p < 0.001). YOPNET was associated with a greater improved OS than TOPNET before and after propensity score matching (p < 0.001). On multivariable analysis, this survival difference persisted for YOPNET as an independent prognostic factor (unmatched p = 0.008; matched p = 0.01). For genomic analysis, patients with YOPNET had a lower rate of multiple endocrine neoplasia type-1 (MEN-1) mutation than patients with TOPNET (26% vs. 56%, p < 0.001). Conclusions: YOPNET represents a disease with distinct clinical features. Patients with YOPNET who underwent definitive surgery had better OS than patients with TOPNET despite having higher stage and tumor size. YOPNET also had lower rate of MEN-1 mutation.

15 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Suleyman GoksuSuleyman Goksu
Suleyman Goksu
Muhammet OzerMuhammet Ozer
Muhammet Ozer
MBMuhammad Shaalan Beg
Muhammad Shaalan Beg
NSNina N Sanford
Nina N Sanford
Chul AhnChul Ahn
Chul Ahn
SKSyed Kazmi
Syed Kazmi
Background: We studied the effect of race and ethnicity on disease characteristics and survival in gastrointestinal neuroendocrine tumors. Methods: The Surveillance, Epidemiology, and End Results database was used to select patients with non-pancreatic gastrointestinal neuroendocrine tumors diagnosed between 2004 and 2015. Trends in survival were evaluated among three groups: Hispanic, non-Hispanic White, and non-Hispanic Black. Kaplan–Meier and Cox regression methods were performed to calculate overall survival and cause-specific survival after adjusting for patient and tumor characteristics. Results: A total of 26,399 patients were included in the study: 65.1% were non-Hispanic White, 19.9% were non-Hispanic Black, and 15% were Hispanic. Non-Hispanic White patients were more likely to be male (50.0%, p < 0.001), older than 60 years (48.0%, p < 0.001), and present with metastatic disease (17.7%, p < 0.001). Non-Hispanic White patients had small intestine neuroendocrine tumors, while Hispanic and non-Hispanic Black patients had rectum neuroendocrine tumors as the most common primary site. Hispanic patients had better overall survival, while non-Hispanic Black patients had better cause-specific survival versus non-Hispanic White patients. This finding was confirmed on multivariable analysis where Hispanic patients had improved overall survival compared to non-Hispanic White patients (Hazard ratio (HR): 0.89 (0.81–0.97)), whereas non-Hispanic Black patients had better cause-specific survival compared to non-Hispanic White patients (HR: 0.89 (0.80–0.98)). Conclusions: Race/ethnicity is an independent prognostic factor in patients with gastrointestinal neuroendocrine tumors.